Companies Dominating the BCL-2 (B-cell lymphoma 2) Inhibitors Market
- Abcam plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Amgen Inc.
- Ascentage Pharma Group International
- Seagen Inc.
- Servier
- AbbVie Inc.
- F. Hoffmann La Roche Ltd.
- Ipsen Pharma
- Merck and Co. Inc.
- Novartis AG
Browse Key Market Insights with Data Illustration:
In the News
- Amgen Inc. acquired ChemoCentryx, Inc. to expand its product portfolio that includes TAVNEOS, an orally given selective complement 5a receptor inhibitor. Furthermore, TAVNEOS was approved by the United States Food and Drug Administration (FDA) in 2021 as an adjunctive therapy for adults with severe active ANCA-associated vasculitis and is being explored in new inflammatory disorders, including hidradenitis suppurativa (HS), a severe and deforming chronic dermatological condition.
- Ascentage Pharma Group International teamed up with Pfizer Inc. to investigate the combination of Ascentage Pharma's lisaftoclax (APG-2575), a Bcl-2 selective inhibitor, and Pfizer's IBRANCE® (palbociclib), a CDK4/6 inhibitor, to assess the safety, tolerability, and anticancer efficacy of lisaftoclax in combination with palbociclib.in patients with metastatic breast cancer.
